

OREGON

Medical office update



APRIL 2022

In this issue

- Emerging Health
- COVID-19 Therapeutics Locator
- Retacrit supply disruption
- Medicare Part B Step Therapy update
- 2022 Moda Health Medicare Advantage and Summit Health Value-Based Contract
- OHA Behavioral Health Initiative Factsheet
- Reimbursement Policy updates
- Medical Necessity updates

Join our email list

[Join our email list](#) in order to begin receiving bi-monthly newsletters, as well as occasional electronic communications.

Changes to Moda Health's Enteral Therapy Network

Starting March 15, 2022, Option 1 Northwest Enteral LLC is no longer an in-network provider with Moda Health. To continue providing statewide enteral services to our Oregon members, we are excited to announce a new partnership with Emerging Health.

Emerging Health is a new, locally owned and operated home infusion and statewide enteral therapy provider in Southwest Portland. Emerging Health offers the following services and therapies:

- **Enteral therapy:** Local 1:1 education, monitoring and assessments from board-certified nutrition support clinicians for tube-fed patients.
- **Home infusion:** Patients can receive treatment in the comfort of their homes. Personalized care options give patients freedom that fits their lifestyle.
- **Ambulatory Infusion Center (AIC):** The ambulatory facility located in Southwest Portland provides a safe and supportive setting for patients and caregivers. Patients receive care in a private infusion suite. They also have a suite designed just for children.

An extension of care

Emerging Health strives to exceed expectations and ensure patients and their caregivers have positive and thoughtfully coordinated experiences. They see their service as an extension of the great care you and your staff provide, including:

- Ensures safety, comfort and convenience by offering treatment in one of their private infusion suites or in the patient's home
- Their local, experienced pharmacy team prepares and packs all medication, supplies and equipment
- Patients receive personalized care plans that incorporate all aspects of their lives
- Their team uses advanced technologies and medical innovations to improve the experience and outcomes of their patients
- You get live, local support to coordinate intake, authorization and billing for Moda Health plan members

To change your patient's prescription to Emerging Health or another in-network enteral provider, just contact one of the resources, below:

Emerging Health

Phone: 877-290-2040

Email: referrals@emerginghealth.com

Moda Health Customer Service

Phone: 888-217-2363

Email: medical@modahealth.com

New COVID-19 Therapeutics Locator

The U.S. Department of Health and Human Services (HHS) has released a new and improved [COVID-19 Therapeutics Locator website](#). The new site uses public HHS data on shipments of U.S. Government-procured COVID-19 therapeutics under U.S. Food and Drug Administration Emergency Use Authorization (EUA) authority.

Therapeutics currently available under EUA include products intended for COVID-19 prevention and monoclonal antibody treatments, including:

Prevention

- Evusheld (AstraZeneca)

Monoclonal antibody treatments

- Bebtelovimab (Lilly)
- Sotrovimab (GSK)

Oral antiviral therapies

- Paxlovid (*Pfizer*)
- Molnupiravir (Merck)

The website displays the number of courses available for each therapeutic, alongside an interactive map. Users can:

- Zoom-in on the area of interest to see data on available therapeutics by location as reported within the last seven days
- Search by location (state, territory or jurisdiction)
- Filter by therapeutic

Search results include location name, address, therapeutic name and NDC, and number of courses available.

Retacrit supply disruption

Pfizer announced it expects a supply disruption for its short-acting erythropoiesis-stimulating agent (ESA), Retacrit (epoetin alfa-ebpx). The forecasted disruption is expected to start May 2022 and last through Q4 2022. In anticipation of the market shortage, Moda Health will temporarily modify our process to minimize the disruption to your patients and practice.

How will this impact you and your patients?

For patients currently receiving Retacrit, you can seamlessly switch to another epoetin alfa agent (Epogen/Procrit), and Moda will cover the drug at the same level as Retacrit.

For patients initiating treatment with an ESA during the shortage, the requirement to use Retacrit before Epogen/Procrit will be waived. Access to Epogen/Procrit will be approved when prior authorization criteria are met during the active shortage period.

Once supply returns, Moda will go back to our pre-shortage policy and process. Providers currently prescribing ESAs will be receiving more information in the mail. You can monitor FDA drug shortages [here](#).

Medicare Part B step therapy updates

On Jan. 1, 2021, Moda Health implemented step therapy requirements for Medicare outpatient (Part B) medications. Step therapy is required for certain medications, but only if the following are met for the requested drug:

- Meets the definition of a Medicare Part B medication
- New for the patient, as defined by no use in the last 365 days
- Proposed use of the requested and alternative drug has been determined to be a medically accepted indication under Medicare rules
- Dose, frequency and duration of use may not exceed the safety and efficacy data supporting the medically accepted indication

Outlined below are the changes to the preferred products **starting July 1, 2022**.

Preferred medication(s) [HCPCS]	Non-preferred medication(s) [HCPCS]
Benlysta [J0490]	Saphnelo [J3590]
Repatha [J9999] OR Praluent [J9999]	Leqvio [J3490]
Avastin - Ophthalmic	Vabysmo [J3590], Susvimo [J3590]

To see the full list of Medicare Part B Step Therapy medications, please visit our [step therapy requirements](#) and [referral and prior authorization guidelines](#) web pages.

Medicare Advantage and Summit Health valued-based contract

At Moda Health and Summit Health, we offer providers to opt-in to the Medicare Advantage Primary Care Incentive Program (MAPCIP). They are eligible to earn a per member per month (PMPM) Care Gap Incentive Payment (CGIP). This rewards performance for meeting set thresholds for quality measure gap closures, as well as an additional PMPM Access to Care Incentive Payment (ACIP) for certain annual physical or wellness visit thresholds.

Your office should have received the 2022 MAPCIP contract. Please complete and return it to contractrenewal@modahealth.com to confirm your participation for this year. You'll also be rewarded for the services you are already providing to your patients.

Questions?

For any questions, please email contractrenewal@modahealth.com.

Behavioral health resources for older adults and people with disabilities

To better meet the needs of older adults and people with disabilities, we're here to improve timely access to care from qualified providers who work together to provide coordinated, quality and culturally responsive behavioral health and wellness solutions.

The Behavioral Health Initiative for Older Adult and People with Physical Disabilities, funded by the Oregon Health Authority, offers resources for both providers and patients. The [website](#) includes training modules for providers, a listing of [upcoming events](#), and other resources to help you support your patients.

Please reference their [Expanding Behavioral Health Services through Medicare Factsheet](#) to see how behavioral health services can be delivered under Medicare. This includes billing codes for Health and Behavioral Assessment and Intervention (HBAI) and Behavioral Health Integration (BHI).

Reimbursement Policy Updates

The following tables include RPM policy updates for December 2021 and January 2022.

Policy	Summary of update
Reviewed in February 2022	
RPM005, "Records Fees, Copying Fees"	<ul style="list-style-type: none"> ● Scope – Added Summit Health ● Information added for Texas ● Acronym table – Added ● Coding Guidelines & Sources – Added ● References & Resources – Added seven listings ● Converted to outline format. Other minor rewording; no content changes.
RPM020, "Maternity Care"	<ul style="list-style-type: none"> ● Sections J.1., O.1., O.1.b.i. – Reworded for Texas ● Section O.1.b.ii. – Added for Texas ● References & Resources – Added # 24 & 25
RPM024, "Modifier SL - State Supplied Vaccine"	<ul style="list-style-type: none"> ● Scope – Added Summit Health ● Acronym table – Added ● Coding Guidelines – Added Texas information ● References & Resources – Added # 7 ● Minor formatting adjustments
RPM052, "Telehealth and Telemedicine Services"	<ul style="list-style-type: none"> ● Modifier 93 (new for 2022) information added ● Section B & Definition of Terms – Telemedicine Note 1 – Updated for HB 2508 updates to ORS 743A.058 ● Section B.10.a. – Additional wording & examples added ● Section D – Added for Texas ● Section E.2.a.ii., E.2.e., – Added from transmittal R11219BP ● Acronym Table – Added 2 entries ● References & Resources – Added # 33 - 37. Updated # 20 ● Other minor rewording; no content changes
Clarification, no policy changes:	
RPM053, "Diagnosis Code Requirements – Level of Detail, Number of Characters, and Laterality"	<ul style="list-style-type: none"> ● Sections B.4 & B.5 - Clarification per provider inquiry received
Annual review:	
RPM015, "Drugs and Biologicals, Wastage and/or Discarded Amounts (Modifier JW)"	<ul style="list-style-type: none"> ● Scope – Added Summit Health plan ● Acronym table – Added ● Minor formatting adjustments & minor rewording
RPM016, "Clinical Drug Screening and/or Drug Testing"	<ul style="list-style-type: none"> ● Scope – Added Summit Health plan ● Acronym table – Added ● Archived 2016 information ● Formatting improvements, minor rewording without content changes
RPM019, "Valid Modifier to Procedure Code Combinations"	<ul style="list-style-type: none"> ● Scope – Added Summit Health plan ● Acronym table – Added ● Archived 2016 information ● Formatting improvements, minor rewording without content

	changes
RPM045, "Reference (Outside) Laboratory – Modifier 90"	<ul style="list-style-type: none"> ● Scope – Added Summit Health. Removed EOCCO ● Acronym table – Added ● Other minor rewording; no content changes
RPM057, "Modifier 50 – Bilateral Procedure"	<ul style="list-style-type: none"> ● Scope – Added Summit Health. Removed EOCCO ● Acronym table – Added 6 listings. EOCCO removed ● Formatting improvements, rewording without content changes

Policy Summary of update

RPM063, "340B Drug Discount Program-Acquired Drugs and Biologicals (Modifiers JG & TB)"	<ul style="list-style-type: none"> ● Scope – Added Summit Health ● Acronym table – Added 8 listings. EOCCO removed. ● Formatting improvements, rewording without content changes
---	---

Reviewed in March 2022

Revision/update:

RPM073, "Telehealth and Telemedicine Expanded Services for COVID-19"	<ul style="list-style-type: none"> ● Section B.2. – added to address modifier 93 ● Changed Header listing of "Section" from "Medicine" to "Administrative" to match RPM052 ● Section B.6: added 3 footnotes ● References & Resources: Updated # 21. Added # 27 - 29.
--	--

Annual review:

RPM021, "Medical, Surgical, and Routine Supplies (including but not limited to 99070)"	<ul style="list-style-type: none"> ● Scope - Added Summit Health ● Formatting improvements, no content changes
RPM022, "Modifier 51 - Multiple Procedure Fee Reductions"	<ul style="list-style-type: none"> ● Scope – Updated listing for Summit Health ● Formatting improvements, rewording without content changes
RPM025, "Add-on Codes"	<ul style="list-style-type: none"> ● Scope – Added Summit Health
RPM026, "Operating Microscope (CPT Code 69990)"	<ul style="list-style-type: none"> ● Scope – Added Summit Health ● Formatting improvements, rewording without content changes
RPM048, "Moderate (Conscious) Sedation"	<ul style="list-style-type: none"> ● Scope – Added Summit Health ● Acronym Table: Added 9 entries

Medical Necessity Criteria updates

The following table includes medical criteria updates for February 2022.

Criteria	February Medical Criteria Summary	Pharmacy/medical
Allergy testing – Blood	<p>Introduction: This is an annual review.</p> <p>Criteria changes:</p> <ul style="list-style-type: none"> ● Listed ICD 10 codes that may not be covered with requests for ALCAT using CPT code 83516 ● Removed ALCAT testing 	Medical

	Investigational indication, retains noncovered indication with listed Dx codes	
Cardiac disease screening – Lipid profile	Introduction: This is an annual review Criteria changes: No changes	Medical
External infusion insulin pumps	Introduction: This is an annual review. Criteria changes: <ul style="list-style-type: none"> Indicated pumps and supplies are FDA approved History of recurring hypoglycemia changed to less than 70 mg/dl 	Medical
Extracorporeal shock wave treatment	Introduction: This is an annual review Criteria changes: No changes	Medical
Kyphoplasty/ Vertebroplasty	Introduction: This is an annual review Criteria changes: No changes	Medical
Obstructive sleep apnea – Surgical treatment	Introduction: This is an annual review Criteria changes: No changes	Medical
Prophylactic mastectomy	Introduction: This is an annual review Criteria changes: No changes	Medical
Skin & tissue substitutes – Engineered	Introduction: This is an annual review. Criteria changes: New 2022 codes added, updated renamed skin substitute- Kerecesis omega 3 wound, added EpiCord to the guidelines section	Medical
Virtual colonoscopy	Introduction: This is an annual review Criteria changes: No changes	Medical

Contact us

Moda Health Medical Customer Service

For claims review, adjustment requests and/or billing policies, please call 888-217-2363 or email medical@modahealth.com.

Moda Provider Relations

For escalated claim inquiries, contract interpretation, educational opportunities or onsite visit requests please email providerrelations@modahealth.com

Provider Updates

For provider demographic and address updates, please email providerupdates@modahealth.com.

Credentialing Department

For credentialing questions and requests, please email credentialing@modahealth.com.



